The history of the erectile dysfunction drug presents a complex picture for shareholders. While the initial launch generated massive gains, the lapse of its intellectual property protection opened the floodgates to https://privatebookmark.com/story21630926/the-copyright-and-the-pharmaceutical-industry-a-risky-opportunity